International journal of reproductive biomedicine · 2025
The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trial studies.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sene Azadeh Akbari, Saeedzarandi Maryam, Yazdizadeh Maryam, Ghaffari Seyede Razieh, Amjadi Fatemehsadat, Zandieh Zahra, Moradi Yousef
Аннотация
BACKGROUND: Conflicting evidence from clinical trials on the effects of myo-inositol and D-chiro-inositol on assisted reproductive technology (ART) outcomes in women with polycystic ovarian syndrome (PCOS) necessitates a systematic review and meta-analysis.
OBJECTIVE: To evaluate the effect of myo-inositol and D-chiro-inositol on ART outcomes in women with PCOS.
MATERIALS AND METHODS: A comprehensive search was conducted in PubMed, Scopus, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Library for studies published from January 2000-2023. Statistical analyses were performed using STATA version 17.
RESULTS: 17 intervention studies were included. myo-inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25-2.15; I2 = 13.5%; p = 0.32) and top-grade embryos (RR: 1.12, 95% CI: 1.02-1.23; I2 = 85.43%; p = 0.0001). However, it was associated with reductions in antral follicle count (WMD: -0.78, 95% CI: -1.07 to -0.49; I2 = 97.37%; p = 0.001) and anti-Mullerian hormone levels (WMD: -0.46, 95% CI: -0.67 to -0.25; I2 = 91.95%; p = 0.001).
CONCLUSION: This meta-analysis provides reliable evidence on the effects of myo-inositol/D-chiro-inositol on fertility and ovarian function in women with PCOS undergoing ART.
OBJECTIVE: To evaluate the effect of myo-inositol and D-chiro-inositol on ART outcomes in women with PCOS.
MATERIALS AND METHODS: A comprehensive search was conducted in PubMed, Scopus, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Library for studies published from January 2000-2023. Statistical analyses were performed using STATA version 17.
RESULTS: 17 intervention studies were included. myo-inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25-2.15; I2 = 13.5%; p = 0.32) and top-grade embryos (RR: 1.12, 95% CI: 1.02-1.23; I2 = 85.43%; p = 0.0001). However, it was associated with reductions in antral follicle count (WMD: -0.78, 95% CI: -1.07 to -0.49; I2 = 97.37%; p = 0.001) and anti-Mullerian hormone levels (WMD: -0.46, 95% CI: -0.67 to -0.25; I2 = 91.95%; p = 0.001).
CONCLUSION: This meta-analysis provides reliable evidence on the effects of myo-inositol/D-chiro-inositol on fertility and ovarian function in women with PCOS undergoing ART.